A study on safety and immune response of investigational RSV OA vaccine in combination with Herpes zoster vaccine in healthy adults

Trial Identifier: 219331
Sponsor: GlaxoSmithKline
Start Date: July 2023
Primary Completion Date: February 2024
Study Completion Date: July 2024
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada Brampton, Canada, L6T 0G1
Canada Guelph, Canada, N1H 1B1
Canada Quebec, Canada, G6W 0M5
Canada Quebec, Canada, J7J 2K8
Canada Quebec, Canada, H9R 4S3
Canada Quebec, Canada, G1N 4V3
Canada Sarnia, Canada, N7T 4X3
Canada Sherbrooke, Canada, J1L 0H8
Canada Toronto, Canada, M3H 5S4
Canada Toronto, Canada, M4G 3E8
Canada Toronto, Canada, M9V 4B4
Canada, ON Brampton, ON, Canada, L6T 0G1
Canada, ON Guelph, ON, Canada, N1H 1B1
Canada, ON Toronto, ON, Canada, M4G 3E8
Canada, ON Toronto, ON, Canada, M9V 4B4
Canada, QC Quebec, QC, Canada, G6W 0M5
Canada, QC Quebec, QC, Canada, J7J 2K8
Canada, QC Quebec, QC, Canada, H9R 4S3
Canada, QC Quebec, QC, Canada, G1N 4V3
Canada, QC Sherbrooke, QC, Canada, J1L 0H8
United States, AL Daphne, AL, United States, 36526
United States, AZ Tempe, AZ, United States, 85281
United States, CA Corte Madera, CA, United States, 94925
United States, CO Aurora, CO, United States, 80012
United States, FL North Miami Beach, FL, United States, 33162
United States, FL West Palm Beach, FL, United States, 33409
United States, GA Columbus, GA, United States, 31904-8946
United States, KY Versailles, KY, United States, 40383
United States, LA New Orleans, LA, United States, 70115
United States, TX Fort Worth, TX, United States, 76104
United States, TX San Antonio, TX, United States, 78229